Description
Dasatinib Tablet is a kinase inhibitor indicated for the treatment of Â
- Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The trial is ongoing and further data will be required to determine long-term outcome.Â
- Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.Â
- Adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Dosage and Side Effects
-
Chronic phase CML: 100 mg once daily.
-
Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL: 140 mg once daily.Â
Administer orally, with or without a meal. Tablets should not be crushed or cut.
FAQ's
Is Dasatinib approved by the FDA?
The FDA approved Dasatinib in 2006.
What is the indication for use of Dasatinib?
The medicine Dasatinib is recommended for the treatment of:Â Â
- Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
- Philadelphia chromosome-positive acute lymphoblastic leukemia.
- chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML.
Is Dasatinib a chemo drug?
Dasatinib is an oral anticancer targeted therapy classified as a BCR-ABL tyrosine kinase inhibitor (TKI) and is used to treat certain types of blood or bone marrow cancer.